Efficacy and Safety of Chinese Herbal Medicine for COVID- 19: a protocol for systematic review and meta-analysis
Item Preview
There Is No Preview Available For This Item
This item does not appear to have any files that can be experienced on Archive.org.
Show all files
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The patients of COVID-19 usually present with fever, cough, while about 23.7% of patients are accompanied by at least one coexisting disease. The disease is highly contagious with a R0 value about 3-4. The rapid increase in the number of patients put great pressure on the health care system. With the aggravation of the shortage of medical treatment, the mortality rate of the disease increases. As of 15:00 on March 31, 2020, 793278 people were diagnosed with the disease and at least 38545 died.
At present, there is no specific cure for this disease, and the clinical management mainly depends on supportive treatment. Lopinavir-Ritonavir was once thought to be a promising medicine on COVID-19, but a recently published clinical trial found that the effect was limited. As excessive immune response is an important reason for the progression of the patient's condition, the researchers turned their attention to immunosuppressants. In a small sample clinical trial, the researchers found that Hydroxychloroquine could improve the state of patients' lungs and increase the probability of the virus turning negative. However, the sample size of this study is small, and there may be some defects in the research design. In a case report, Remdesivir has shown good efficacy in patients with COVID-19, and larger clinical trials are currently under way. Therefore, it is an important and urgent task to explore new therapeutic agents.
In the fourth edition of the diagnosis and treatment guideline of COVID-19 in China, Lianhuaqingwen capsule was listed as one of the recommended medicines. In addition, traditional Chinese medicines (CHM), including Qingfei Paidu decoction, Huanglian Jiedu decoction etc., are also widely used in the adjuvant treatment of COVID-19. In terms of clinical research, many scholars have carried out clinical trials on the efficacy of CHM in treating COVID-19. However, these studies are only carried out in local areas, so they fail to provide definite evidence to prove the effectiveness of CHM. In this study, we aim to summarize the current evidence of CHM in treating COVID-19 through systematic review and meta-analysis. This study is necessary before further large-scale clinical studies being carried out. For clinicians, this study can provide some direction and guidance for clinical practice.
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The patients of COVID-19 usually present with fever, cough, while about 23.7% of patients are accompanied by at least one coexisting disease. The disease is highly contagious with a R0 value about 3-4. The rapid increase in the number of patients put great pressure on the health care system. With the aggravation of the shortage of medical treatment, the mortality rate of the disease increases. As of 15:00 on March 31, 2020, 793278 people were diagnosed with the disease and at least 38545 died.
At present, there is no specific cure for this disease, and the clinical management mainly depends on supportive treatment. Lopinavir-Ritonavir was once thought to be a promising medicine on COVID-19, but a recently published clinical trial found that the effect was limited. As excessive immune response is an important reason for the progression of the patient's condition, the researchers turned their attention to immunosuppressants. In a small sample clinical trial, the researchers found that Hydroxychloroquine could improve the state of patients' lungs and increase the probability of the virus turning negative. However, the sample size of this study is small, and there may be some defects in the research design. In a case report, Remdesivir has shown good efficacy in patients with COVID-19, and larger clinical trials are currently under way. Therefore, it is an important and urgent task to explore new therapeutic agents.
In the fourth edition of the diagnosis and treatment guideline of COVID-19 in China, Lianhuaqingwen capsule was listed as one of the recommended medicines. In addition, traditional Chinese medicines (CHM), including Qingfei Paidu decoction, Huanglian Jiedu decoction etc., are also widely used in the adjuvant treatment of COVID-19. In terms of clinical research, many scholars have carried out clinical trials on the efficacy of CHM in treating COVID-19. However, these studies are only carried out in local areas, so they fail to provide definite evidence to prove the effectiveness of CHM. In this study, we aim to summarize the current evidence of CHM in treating COVID-19 through systematic review and meta-analysis. This study is necessary before further large-scale clinical studies being carried out. For clinicians, this study can provide some direction and guidance for clinical practice.
- Osf_project
-
https://api.osf.io/v2/nodes/8bqj5/?version=2.20
- Source
-
https://osf.io/2pt6u/
Reviews
There are no reviews yet. Be the first one to
write a review.
